8-K: Adicet Bio Provides Clinical Trial Enrollment Updates at Guggenheim Securities Conference

Adicet Bio announces enrollment updates for its ADI-001 and ADI-270 clinical programs at the Guggenheim Securities SMID Cap Biotech Conference.

Summary

• Adicet Bio provided an update on the enrollment status of its clinical programs at the Guggenheim Securities SMID Cap Biotech Conference on February 5, 2025.
• The company has enrolled 3 patients in its Phase 1 Lupus Nephritis (LN) clinical trial for ADI-001, with the first patient dosed in November 2024.
• Approximately 12 sites have been activated for the LN trial, and preliminary results are expected in the first half of 2025.
• Adicet anticipates initiating Phase 1 patient enrollment for ADI-001 in systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathy, and stiff person syndrome in the first quarter of 2025, with preliminary data expected in the second half of 2025.
• Patient enrollment in anti-neutrophil cytoplasmic autoantibody associated vasculitis is expected to begin in the second half of 2025.
• The company has enrolled 3 patients in its Phase 1 ccRCC program for ADI-270, with the first patient dosed in December 2024.
• Approximately 7 sites have been activated for the ccRCC trial, and preliminary results are expected in the first half of 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company is progressing with its clinical trials and expanding its programs. However, the presence of forward-looking statements and associated risks tempers the overall sentiment.

Positives

• Enrollment is progressing in both the ADI-001 Lupus Nephritis and ADI-270 ccRCC Phase 1 clinical trials.
• The company anticipates reporting preliminary results from both trials in the first half of 2025.
• Adicet is expanding the ADI-001 program to include additional autoimmune indications, with enrollment expected to begin in the first quarter of 2025.

Risks

• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• These risks include the effect of global economic conditions and public health crises, the ability to obtain regulatory approvals, and the possibility that clinical studies may not demonstrate adequate safety and efficacy.
• Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable.
• Adicet's ability to meet production and product release expectations is also a risk factor.

Future Outlook

Adicet Bio anticipates reporting preliminary results from the Phase 1 LN clinical trial and the Phase 1 ccRCC program in the first half of 2025. The company also expects to initiate Phase 1 patient enrollment for ADI-001 in additional autoimmune indications in the first quarter of 2025, with preliminary data expected in the second half of 2025. Patient enrollment in anti-neutrophil cytoplasmic autoantibody associated vasculitis is expected to begin in the second half of 2025.

Industry Context

The announcement reflects the ongoing interest and investment in allogeneic CAR T-cell therapies for both cancer and autoimmune diseases. Several companies are pursuing similar approaches, and Adicet's progress will be closely watched by investors and competitors alike.

Comparison to Industry Standards

• Adicet is competing with companies like Allogene Therapeutics and CRISPR Therapeutics in the allogeneic CAR T-cell therapy space.
• The timelines for Adicet's clinical trials appear to be in line with industry standards for Phase 1 studies.
• Success in these trials would position Adicet favorably against competitors in the development of off-the-shelf CAR T-cell therapies.

Stakeholder Impact

• Positive enrollment updates could increase shareholder confidence.
• Successful clinical trial results could lead to increased investment and potential partnerships.
• Patients with Lupus Nephritis, Renal Cell Carcinoma, and other autoimmune diseases may benefit from the development of new therapies.

Next Steps

• Continue patient enrollment in the Phase 1 LN and ccRCC clinical trials.
• Initiate Phase 1 patient enrollment for ADI-001 in additional autoimmune indications in the first quarter of 2025.
• Report preliminary results from the Phase 1 LN and ccRCC trials in the first half of 2025.
• Report preliminary data from the additional autoimmune cohorts in the second half of 2025.
• Begin patient enrollment in anti-neutrophil cytoplasmic autoantibody associated vasculitis in the second half of 2025.

Key Dates

Keywords

Adicet Bio, Clinical Trial, ADI-001, ADI-270, Lupus Nephritis, Renal Cell Carcinoma, Autoimmune, Enrollment, CAR T cell therapy